Squarepoint Ops LLC Buys New Position in Abeona Therapeutics Inc (NASDAQ:ABEO)

Squarepoint Ops LLC bought a new position in Abeona Therapeutics Inc (NASDAQ:ABEO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,028 shares of the biopharmaceutical company’s stock, valued at approximately $67,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after buying an additional 652,366 shares in the last quarter. 683 Capital Management LLC raised its position in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after buying an additional 116,845 shares during the last quarter. Bank of America Corp DE raised its position in Abeona Therapeutics by 16.7% in the 4th quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company’s stock worth $1,473,000 after buying an additional 37,774 shares during the last quarter. Northern Trust Corp grew its stake in shares of Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 118,262 shares during the period. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Stock Performance

Shares of NASDAQ:ABEO opened at $6.46 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The business’s 50 day moving average price is $5.62 and its 200-day moving average price is $5.58. The firm has a market capitalization of $330.47 million, a PE ratio of -2.40 and a beta of 1.54. Abeona Therapeutics Inc has a 1 year low of $3.93 and a 1 year high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.11. As a group, equities research analysts expect that Abeona Therapeutics Inc will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABEO. Stifel Nicolaus cut their price target on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Alliance Global Partners restated a “buy” rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. HC Wainwright upped their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, April 30th. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 15th. Finally, Oppenheimer began coverage on Abeona Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Abeona Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $19.25.

Insider Buying and Selling

In related news, CFO Joseph Walter Vazzano sold 17,795 shares of the company’s stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $6.76, for a total value of $120,294.20. Following the completion of the sale, the chief financial officer now directly owns 491,246 shares of the company’s stock, valued at $3,320,822.96. This represents a 3.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the transaction, the chief executive officer now directly owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. This trade represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,941 shares of company stock valued at $711,341 in the last three months. 6.90% of the stock is owned by corporate insiders.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.